G-protein Coupled Receptors Market - Databook 2025 to 2034

The global G-protein coupled receptors market size was evaluated at USD 3,940 million in 2024 and is expected to grow around USD 7,190 million by 2034, registering a CAGR of 6.2% from 2025 to 2034.

G-protein Coupled Receptors Market Report Highlights

• North America dominated the G-protein coupled receptors market with the largest revenue share in 2024.
• Asia Pacific is expected to grow at the fastest CAGR during the forecast period.
• By product, the cell lines segment dominated the G-protein coupled receptors market with the largest revenue share in 2024.
• By product, the detection kits segment is expected to grow the fastest during the forecast period.
• By assay type, the cAMP functional segment dominated the market with the largest revenue share in 2024.
• By assay type, the calcium functional segment is expected to grow significantly during the forecast period. 580
• By application, the cancer research segment dominated the market and accounted for the highest revenue share in 2024.
• By application, the CNS research segment is expected to grow with a significant CAGR during the forecast period.

Industry Valuation and Growth Rate Projection

The G-protein coupled receptors market refers to the production, distribution, and application of G-protein coupled receptors (GPCR) are cell surface receptors that pass on the signals that they receive with the help of guanine nucleotide-binding proteins. G-protein coupled receptors are defined as a major group of cellular receptors found on various types of cells, including neurons, that exhibit significant plasticity. These receptors are activated by many stimuli, such as odorants, chemokines, neurotransmitters, hormones, and others. 

GPCRs influence broad physiological processes such as cellular metabolism, neurotransmission, cell growth, secretion, and immune responses. Receptors are a special class of proteins that function by binding a specific ligand molecule. When a ligand binds to its receptor, the receptor can change conformation, transmitting a signal into the cell. In some cases, the receptors will remain on the surface of the cell, and the ligand will eventually diffuse away. There is no doubt that this family of membrane proteins plays an important role in drug discovery. Traditionally, several drugs based on GPCRs have been developed for such different indications as cardiovascular, metabolic, neurodegenerative, psychiatric, and oncologic diseases.

Increasing prevalence of chronic diseases driving the growth of the G-protein coupled receptors market. G-protein-coupled receptors have emerged as important drug targets for many chronic diseases, including obesity and diabetes. Vascular diseases like atherosclerosis lead to characteristic changes in the expression of GPCRs. Thus, in the vascular system, GPCRs are critical regulators. GPCRs regulate blood pressure by modulating the dynamic balance of vasoconstriction and relaxation.

Characterizing the physiological functions of GPCRs in the nervous system and pathological mechanisms in the disease models can accelerate GPCR-targeted drug development. Mutations in GPCR can cause acquired and inherited diseases such as retinitis pigmentosa (RP), hypo- and hyperthyroidism, nephrogenic diabetes insipidus, many fertility disorders, and even carcinomas. GPCRs, also known as seven transmembrane domain receptors, are the largest receptor family in the human genome, with nearly 800 members. GPCR nearly every aspect of human physiology and disease, thus serving as an important drug target in cardiovascular disease.

Increasing investment in research and development (R&D) is driving the growth of the G-protein coupled receptors market. Investing in R&D directly contributes to overall global success for many reasons. R&D drives advancements, improves competitive benefits, facilitates market expansion, and contributes to sustainable development. Investments in R&D benefits include more informed decision-making and risk mitigation. Data science, machine learning (ML), and artificial intelligence (AI) are empowering investment research analysts to process high amounts of data rapidly and derive actionable insights. R&D can be improved by forming strategic alliances, preserving data integrity, risk-based quality management, leveraging big data mining, business process management, and priority management. R&D involves researching your market and your customers' needs and developing new and enhanced products and services to fit these needs.

Technological advancements in biased agonists, allosteric modulators, and biological drugs are driving the growth of the G-protein coupled receptors market. Allosteric modulators represent an innovative class of drugs, potentially offering higher target/functional selectivity, fewer adverse on- and off-target effects, and lower toxicity in comparison to orthosteric ligands. The structure of GPCRs is a crucial determinant for understanding the molecular mechanisms underlying ligand recognition and receptor activation. It provides a foundation for drug discovery. Biased ligands are compounds that promote selective activation of specific signaling pathways in G-protein coupled receptors, leading to distinct pharmacological responses.

• According to a report published in January 2024 by IQVIA, the Global Use of Medicines 2024,
• Historical and projected use of medicines by region, 2018-2028, Defined Daily Doses (DDD) in billions,